Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0902 • ACR Convergence 2020
Impact of Dose Escalation of Secukinumab in Patients with Psoriatic Arthritis in Real-World Setting
Maria Martin-Lopez¹, Beatriz Joven² and Jose Luis Pablos¹, ¹Hospital 12 de Octubre, Madrid, Spain, ²Hospital Universitario 12 de Octubre, Madrid, Spain
Background/Purpose: Secukinumab (SEC) has provided efficacy in clinical trials in patients with psoriatic arthritis (PsA). In PsA patients, a gain in response has been suggested…
Abstract Number: 1318 • ACR Convergence 2020
Catastrophizing in Patients with Axial Spondyloarthritis and Psoriatic Arthritis
Baptiste Coste¹, Charlotte Traverson¹, Elisabeth Filhol¹, Soraya Benamar¹, Jacques Morel², Sabine Laurent-Chabalier³, Bernard Combe⁴, Claire Daien², Cédric Lukas⁵, Charlotte Hua¹ and Cecile Gaujoux-Viala⁶, ¹Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, Nimes, France, ²Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, ³Department of Biostatistics, Clinical Epidemiology, Public Health and innovation in Methodology, CHU Nîmes, University of Montpellier-Nîmes, France, Nimes, France, ⁴University of Montpellier, Montpellier, France, ⁵CHU Montpellier and University of Montpellier, Montpellier, France, ⁶Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France
Background/Purpose: Catastrophizing is a negative cognitivo-affective response to an anxiety-provoking stimulus, especially to pain. Catastrophism plays a role in maintaining chronic pain and is associated…
Abstract Number: 1352 • ACR Convergence 2020
Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension
Joseph Merola¹, Frank Behrens², Alan Kivitz³, Philip Mease⁴, Iain McInnes⁵, Barbara Ink⁶, Deepak Assudani⁷, Paulatsya Joshi⁷, Jason Coarse⁸ and Christopher Ritchlin⁹, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ³Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁵Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶UCB Pharma, Slough, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Raleigh, NC, ⁹Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes over…
Abstract Number: 1543 • ACR Convergence 2020
Prevalence of Ultrasound Findings Suggestive of Inflammatory Arthritis in Children with Skin Psoriasis (ChildEchoPso)
Luis Coronel¹, Tania Gudu², Sophie Ruel-Gagné¹, Helen Gouze³, Francois Vidal⁴, Ilaria Padovano⁴, Felice Constantino², Maxime Breban⁴, Emmanuel Mahe⁵ and Maria Antonietta D'Agostino⁶, ¹Hôpital Ambroise-Paré, Boulogne-Billancourt, France, ²Hôpital Ambroise-Paré, Bolougne-Billancourt, France, ³[email protected], Bolougne-Billancourt, France, ⁴Hôpital Ambroise-Paré, Bolougne-Billancourt, ⁵Centre Hospitalier Victor Dupouy, Argenteuil, France, ⁶Paris-Saclay Versailles University, Hôpital Ambroise Paré, Boulogne-Billancourt, France
Background/Purpose: The prevalence of psoriasis in children is estimated between 0.5-1% (1), and can be associated with musculoskeletal involvement, althought the prevalence and typology of…
Abstract Number: 2015 • ACR Convergence 2020
Prevalence and Distribution of Peripheral Musculoskeletal Manifestations in Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis: Results of the International, Cross-sectional ASAS-PerSpA Study
Clementina Lopez-Medina¹, Anna Molto¹, Joachim Sieper², Mehmet Tuncay Duruöz³, Uta Kiltz⁴, Bassel El-Zorkany⁵, Najia Hajjaj-Hassouni⁶, Ruben Burgos-Vargas⁷, Jose Maldonado-Cocco⁸, Nelly Ziade⁹, Meghna Gavali¹⁰, Victoria Navarro-Compán¹¹, Shue Fen Luo¹², Sara Monti¹³, Tae-Jong Kim¹⁴, Mitsumasa Kishimoto¹⁵, Fernando Pimentel-Santos¹⁶, Jieruo Gu¹⁷, Ruxandra Schiotis¹⁸, Floris van Gaalen¹⁹, Pál Géher²⁰, Marina Magrey²¹, Sebastian Ibanez²², Wilson Bautista-Molano²³, Walter Maksymowych²⁴, Pedro M Machado²⁵, Robert Landewé²⁶, Désirée van der Heijde²⁷ and Maxime Dougados²⁸, ¹Rheumatology Department, Cochin Hospital, Paris, Paris, France, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey, ⁴Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ⁵Cairo University, Cairo, Egypt, ⁶Health Sciences College, International University of Rabat (UIR), Rabat, Morocco, ⁷Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, ⁸Buenos Aires School of Medicine, Buenos Aires, Argentina, ⁹Saint-Joseph University, Beirut, Lebanon, Beirut, Lebanon, ¹⁰Nizam’s Institute of Medical Sciences, Hyderabad, India, ¹¹Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ¹²Chang Gung Memorial Hospital-Linkou, Taoyuan, Taipei, Taiwan (Republic of China), ¹³Fondazione IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy, ¹⁴Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ¹⁵Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ¹⁶3.CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal; 7.Hospital Egas Moniz (CHLO) (Rheumatology Department), Lisboa, Portugal, Lisbon, Portugal, ¹⁷Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, guangzhou, China (People's Republic), ¹⁸Pharmacology Department Department, Iuliu Hatieganu University of Medicine and Pharmacy, SCBI-Rheumatology Department, Cluj-Napoca, Romania, ¹⁹Leiden University Medical Center (LUMC), Leiden, Netherlands, ²⁰Semmelweis University, Budapest, Hungary, ²¹Case Western Reserve University School of Medicine, Cleveland, OH, ²²Facultad de Medicina Clínica Alemana – Universidad del Desarrollo, Santiago, Region Metropolitana, Chile, ²³University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia, ²⁴University of Alberta, Edmonton, AB, Canada, ²⁵University College London, London, United Kingdom, ²⁶Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ²⁷Leiden University Medical Center, Leiden, Netherlands, ²⁸Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France
Background/Purpose: Peripheral musculoskeletal manifestations in patients with Psoriatic Arthritis (PsA) have been widely studied. However, there is a lack of knowledge on the distribution of…
Abstract Number: 0160 • ACR Convergence 2020
Use of PROMIS29 Across Inflammatory Arthritis: Score Distributions and Impact of Contextual Factors
Alexis Ogdie¹, Kaleb Michaud², Mark Hwang³, Sofia Pedro⁴ and Patricia Katz⁵, ¹University of Pennsylvania, Philadelphia, PA, ²FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita, ³McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁴FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ⁵University of California, San Francisco, Novato, CA
Background/Purpose: The Patient-Reported Outcome Measure Information System (PROMIS) includes a set of instruments developed to measure physical, mental and social health. PROMIS measures have been…
Abstract Number: 0315 • ACR Convergence 2020
The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia
Ari Polachek¹, Victoria Furer², Mirna Zureik³, Sharon Nevo³, Liran Mendel⁴, David Levartovsky², Jonathan Wollman³, Valerie Aloush², Mark Berman², Ilana Kaufman⁵, Reut Tzemach⁴, Marina Anouk⁶, Ofir Elalouf⁷, Hagit Padova⁴, Or Carmi⁸, Tali Eviatar⁹, Yael Lahat goldstein², Hagit Sarbagil-Maman¹⁰, Sara Borok Lev-Ran², Adi Broide³, Lihi Eder¹¹, Daphna Paran² and Ori Elkayam³, ¹Tel Aviv Sourasky Medical Center, Petah-Tikva, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁴Souraaky Medical Center, Tel-Aviv, Israel, ⁵Tel Aviv Sourasky Medical Center, Petah-Tiqwa, Israel, ⁶Souraaky Medical Center, Tel Aviv, Israel, ⁷Souraaky Medical Center, Herzliya, Israel, ⁸Souraaky Medical Center, herzelia, Israel, ⁹Tel Aviv Sourasky Medical Center, Givataim, Israel, ¹⁰Tel-Aviv Sourasky Medical Center, Kiryat Ono, Israel, ¹¹University of Toronto, Toronto, ON, Canada
Background/Purpose: The presence of fibromyalgia (FMS) in psoriatic arthritis (PsA) patients increases the scores of the clinical measures of disease activity. The aim of this…
Abstract Number: 0331 • ACR Convergence 2020
Work Absenteeism and Disability Associated with Psoriatic Arthritis and Psoriasis in the United States – A Retrospective Study of Claims Data from 2009 to 2020
Ana-Maria Orbai¹, Soumya Reddy², Steven Peterson³, Natalie Dennis⁴, Reginald Villacorta⁵, Laura Mesana⁶, Soumya Chakravarty⁷, Maud Pacou⁴, Iris Lin⁵, Thomas Baker⁸, Yiting Wang⁹ and Jessica Walsh¹⁰, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²NYU School of Medicine, New York City, ³Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁴Amaris, Paris, France, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Amaris, New York, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁸Janssen Global Services, LLC, Raritan, NJ, ⁹Janssen R&D, LLC, Titusville, ¹⁰University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Absenteeism and work disability substantially contribute to the economic burden of psoriasis and psoriatic arthritis (PsA). This study compared work absenteeism and short-term disability…
Abstract Number: 0351 • ACR Convergence 2020
Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients
Laure Gossec¹, Elke Theander², Soumya Chakravarty³, Paul Bergmans⁴, Iris Lin⁵, Wim Noël⁶, Stefan Siebert⁷ and Josef Smolen⁸, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²Janssen Cilag, Lund, Sweden, ³Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁴Janssen Biostatistics and Medical Affairs, Tilburg, Netherlands, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Janssen Medical Affairs, LLC, Beerse, Belgium, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: In the PsABio study (NCT02627768), real-world data from patients with PsA showed comparable clinical results after treatment with ustekinumab (UST, an anti-p40 IL-12/23 inhibitor)…
Abstract Number: 0378 • ACR Convergence 2020
Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
Joseph Merola¹, Peter Taylor², Andrew Bushmakin³, Joseph Cappelleri³, Pamela Young⁴, Rebecca Germino⁵ and Gil Yosipovitch⁶, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, New York, NY, ⁶University of Miami, Miami, FL
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease with signs and symptoms across multiple domains, including cutaneous manifestations, which can impact health-related quality…
Abstract Number: 0581 • ACR Convergence 2020
A Proposed Economic Framework to Model the Consequences of Psoriatic Arthritis Disease Domains
Jacquelyn Chou¹, Ervant Maksabedian², David Collier³ and Howard Thom⁴, ¹PRECISION heor, Los Angeles, CA, ²Amgen Inc., LOS ANGELES, CA, ³Amgen, Thousand Oaks, CA, ⁴University of Bristol, Bristol, England, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) manifests heterogeneous signs and symptoms (e.g., dactylitis, enthesitis, axial involvement, skin- and nail disease), which may respond to treatments differently. While…
Abstract Number: 0903 • ACR Convergence 2020
Changing Patterns of Use of Biologic/Targeted Synthetic DMARDs in Psoriatic Arthritis: An Analysis of the OPAL Dataset
Sabina Ciciriello¹, Tegan Smith², Geoffrey Littlejohn³, Kathleen Tymms⁴, David Mathers⁵, Helen Cooley⁶, Hedley Griffiths⁷, Catherine OSullivan² and Peter Youssef⁸, ¹Royal Melbourne Hospital, Melbourne, VIC, Melbourne, Victoria, Australia, ²OPAL Rheumatology Ltd, Sydney, NSW, Kogarah, New South Wales, Australia, ³Monash Rheumatology, Clayton, VIC; OPAL Rheumatology Ltd, Sydney, NSW, Melbourne, Victoria, Australia, ⁴Canberra Rheumatology, Canberra, ACT, Canberra, Australian Capital Territory, Australia, ⁵Georgetown Rheumatology, Georgetown, NSW, Georgetown, New South Wales, Australia, ⁶Hobart Private Hospital, Hobart, TAS, Taroona, Australia, ⁷Barwon Rheumatology Service, Geelong, VIC, Geelong, Victoria, Australia, ⁸University of Sydney, Sydney, NSW; Royal Prince Alfred Hospital, Camperdown, NSW, Camperdown, New South Wales, Australia
Background/Purpose: In Australia the cost of biologic/targeted synthetic DMARDs (b/tsDMARDs) for treatment of PsA is subsidized if the patient has documented high levels of clinical/laboratory…
Abstract Number: 1325 • ACR Convergence 2020
Monoclonal Gammopathy in Psoriatic Arthritis
Vanessa Ocampo¹ and Dafna Gladman², ¹University of Toronto, University Health Network, Psoriatic Arthritis Research Program, Toronto, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant clonal plasma disorder, defined by the presence of a serum monoclonal protein (M-protein) at…
Abstract Number: 1353 • ACR Convergence 2020
Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage
Laura Coates¹, Désirée van der Heijde², Lars Erik Kristensen³, William Tillett⁴, Jason Eells⁵, Tommi Nurminen⁶ and Atul Deodhar⁷, ¹University of Oxford, Oxford, United Kingdom, ²Leiden University Medical Center, Leiden, Netherlands, ³The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Pre-existing structural damage in patients with psoriatic arthritis (PsA) has been suggested to impact therapeutic improvements in disease activity and functional outcomes.1,2 Here we…
Abstract Number: 1546 • ACR Convergence 2020
Ultrasound, Magnetic Resonance Imaging and Radiography of the Fingers’ Joints of Psoriatic Arthritis Patients
Ari Polachek¹, Victoria Furer², Mirna Zureik³, Sharon Nevo³, Liran Mendel⁴, David Levartovsky², Jonathan Wollman⁴, Valerie Aloush², Reut Tzemach⁴, Ofir Elalouf⁵, Marina Anouk⁶, Mark Berman², Ilana Kaufman⁷, Yael Lahat goldstein², Hagit Sarbagil-Maman⁸, Sara Borok Lev-Ran², Adi Broide³, Lihi Eder⁹, Daphna Paran², Moshe Iluz¹⁰, Iris Eshed¹¹ and Ori Elkayam³, ¹Tel Aviv Sourasky Medical Center, Petah-Tikva, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁴Souraaky Medical Center, Tel-Aviv, Israel, ⁵Souraaky Medical Center, Herzliya, Israel, ⁶Souraaky Medical Center, Tel Aviv, Israel, ⁷Tel Aviv Sourasky Medical Center, Petah-Tiqwa, Israel, ⁸Tel-Aviv Sourasky Medical Center, Kiryat Ono, Israel, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰Souraaky Medical Center, Tel-Aviv, ¹¹Sheba Medical Center, Tel-Aviv, Israel
Background/Purpose: Ultrasound (US), magnetic resonance imaging (MRI) and conventional radiography are the leading imaging modalities for musculoskeletal (MSK) assessment in PsA. However, little is reported…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].